Data from more than 3,600 clinically validated sessions provide autism and non-autism peer comparisons, bringing new context to individual development and progress
PLYMOUTH, Minn., — A new application of eye-tracking science is advancing how clinicians interpret autism severity and developmental progress. Drawing on more than 3,600 clinically validated assessment sessions, EarliPoint Health has introduced population-level reference ranges that place a child’s results in the context of both an Autism Peer Sample and a Non-Autism Peer Sample.
The advancement addresses a central challenge in autism care: understanding what an individual child’s assessment results mean over time. Viewing a child’s trajectory alongside two distinct peer samples provides additional context for interpreting social and developmental functioning, informing care discussions, and communicating results to families and payers.
“Measuring change is critical, for families and providers alike; but to accurately interpret change, we need context,” said Ami Klin, PhD, Scientific Co-Founder of EarliPoint Health and a leading autism researcher. “Reference ranges from both autism and non-autism peer samples give us two necessary and complementary perspectives on a child’s development and response to treatment. While grounding clinical interpretation in the child’s individual growth, the reference ranges provide us with the comparisons we need to situate individual results relative to other children with autism as well as to normative expectations.”
A broader reference point for individual development
The reference ranges span three EarliPoint indices: Social Disability, Language Comprehension and Nonverbal Learning. Clinicians can view a child’s scores across assessments alongside the distribution of results within each peer sample, including peer percentiles.
For Language Comprehension and Nonverbal Learning, the reference ranges reflect how skills develop with age. This allows clinicians to consider changes in an individual child’s scores alongside developmental patterns within each peer sample.
The result is a richer framework for discussing a child’s strengths, challenges and progress. It brings together the child’s assessment history and population-level context to support clinical interpretation throughout the care journey.
“Assessment data are most valuable when they help us better understand a child’s development and make informed decisions about care,” said Dennis Dixon, PhD, Chief Clinical Officer of 360 Behavioral Health and a founding member of Project ALIGN. “Having both autism and non-autism reference ranges provides important context for interpreting developmental performance and change over time. This can help clinicians have more meaningful conversations with families and bring greater objectivity and consistency to clinical decision-making.”
Advancing a shared approach to outcomes measurement
The new reference ranges complement the goals of Project ALIGN, the Autism Longitudinal Insights and Growth Network. Convened by EarliPoint Health, the consortium brings together leaders from autism service organizations to advance best practices for longitudinal developmental measurement, clinical interpretation and communication.
In its coverage of EarliPoint’s expanded FDA age indication, Acuity Media highlighted the role of objective assessment beyond diagnosis. The new reference ranges build on that work by giving clinicians more context for interpreting progress over time.
“Our goal is to make objective developmental measurement a standard of care in autism,” said Jamie Pagliaro, President and CEO of EarliPoint Health. “That requires rigorous science and a shared approach to interpreting and using the information. These reference ranges represent an important step toward giving clinicians, families and payers a clearer foundation for discussing each child’s progress across the care journey.”
Bringing established science into longitudinal assessment
EarliPoint uses eye-tracking technology to measure how children visually engage with social information while watching short videos. It translates moment-by-moment looking behavior into objective measurements that complement clinical observation and judgment.
The platform brought the first FDA-cleared objective measurement tool to clinicians to aid in autism diagnosis and assessment in children as young as 16 months. Its scientific foundation includes decades of research and clinical studies published in JAMA and JAMA Network Open.
The new reference ranges are available through EarliPoint’s Developmental Progress Report (DPR), designed for use at baseline and for longitudinal reassessment. The report combines results across sessions with reference-range visualizations, peer percentiles and clinical categories. The DPR is a non-diagnostic report intended to support clinical interpretation and longitudinal assessment.
About EarliPoint Health
EarliPoint Health is a healthcare technology company advancing objective measurement in autism care. Built on decades of research, its FDA-cleared eye-tracking technology provides insights into social and developmental functioning to support qualified clinicians, families and care teams. Through innovations in diagnosis and longitudinal assessment, EarliPoint Health is working to make scientifically grounded developmental information accessible throughout the care journey.
The EarliPoint Assessment device is indicated as a tool to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children ages 16 months through 95 months (7 years), who are at risk based on concerns identified by a parent, caregiver, or healthcare provider. Clinician use only.
Learn more at earlipointhealth.com.
Media Contact:
Nisreen Damatti, Marketing Manager
ndamatti@earlipointhealth.com
833-504-9937



